Stilla Bauernfeind

Dr. Stilla Bauernfeind


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
SBStilla Bauernfeind
Stilla Bauernfeind
BSBernd Salzberger
Bernd Salzberger
FHFlorian Hitzenbichler
Florian Hitzenbichler
KSKarolina Scigala
Karolina Scigala
SESebastian Einhauser
Sebastian Einhauser
DPDavid Peterhoff
David Peterhoff
It is not clear whether there is an association between adverse reactions and immune response after vaccination. Seven hundred and thirty-five vaccinees from our University Medical Center vaccination clinic provided information about sex, age and adverse reactions after first and second vaccination with BNT162b2. Adverse reactions were categorized into three groups: no or minor on the injection side, moderate (not further classified) and severe—defined as any symptom(s) resulting in sick leave. We chose 38 vaccinees with the most severe adverse reactions and compared their humoral and T-cell-mediated immune responses after second vaccination with those of 38 sex and age matched controls without or only minor injection-side related adverse reactions. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-receptor binding domain (RBD) IgG titers were detectable in all participants (median 5528; range 958–26,285). Men with severe adverse reactions had 1.5-fold higher median SARS-CoV-2 RBD IgG titers compared to men without adverse reactions (median 7406 versus 4793; p < 0.001). Similarly; neutralization activity was significantly higher in men with severe adverse reactions (half maximal inhibitory concentrations (IC50) median 769 versus 485; p < 0.001). Reactogenicity did not influence humoral immune response in women nor T-cell-mediated immune response in any sex. To conclude; adverse reactions after vaccination with BNT162b2 do influence humoral immune response yet only in men and are not a prerequisite for a robust antibody response.

10 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
FHFlorian Hitzenbichler
Florian Hitzenbichler
SBStilla Bauernfeind
Stilla Bauernfeind
BSBernd Salzberger
Bernd Salzberger
BSBarbara Schmidt
Barbara Schmidt
JWJürgen J. Wenzel
Jürgen J. Wenzel
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA is detected by reverse-transcription quantitative real-time PCR (RT-qPCR) from respiratory specimens. This study compares throat washings (TW), nasopharyngeal swabs (NS) and oropharyngeal swabs (OS). A total of 102 samples from 34 adult patients with confirmed SARS-CoV-2 infection were analysed by RT-qPCR with absolute quantification. The median concentrations and diagnostic sensitivities were 5.8×104 copies/mL, 85% (NS), 1.4×104, 79% (OS) and 4.3×103, 85% (TW). Concentration differences were significant between NS and TW (P = 0.019). Saliva (SA) was available from 21 patients (median 3.4×103). OS and TW can be considered for SARS-CoV-2 diagnostics, although with slightly lower concentrations.

20 May 2021 in Infection
Verified
Journal Article
Open access
PDF file
SBStilla Bauernfeind
Stilla Bauernfeind
FHFlorian Hitzenbichler
Florian Hitzenbichler
GHGunnar Huppertz
Gunnar Huppertz
FZFlorian Zeman
Florian Zeman
MKMichael Koller
Michael Koller
BSBernd Salzberger
Bernd Salzberger
Coronavirus disease 2019 (Covid-19) vaccination is essential to fight the pandemic. Health care workers (HCWs) are prioritized to get vaccinated, yet uptake of recommended vaccinations is known to be low in this group. In a tertiary care university hospital with a high number of Covid-19 patients in intensive care, 59.5% of surveyed staff (N = 2454) were willing to get vaccinated, 21.4% were unsure and 18.7% refused. Vaccine hesitancy was higher in female, younger and healthy employees without contact to Covid-19 patients; nurses (53.3%) were much less willing to get vaccinated compared to physicians (82.7%).

16 February 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
AMArno Mohr
Arno Mohr
MKMia Kloos
Mia Kloos
CSChristian Schulz
Christian Schulz
MPMichael Pfeifer
Michael Pfeifer
BSBernd Salzberger
Bernd Salzberger
MKMyriam Koch
Myriam Koch
Introduction: The aim of this study was to investigate the adherence to vaccinations, especially pneumococcal vaccinations, in lung cancer patients. Methods: the study was performed at the University Hospital Regensburg, Germany. All patients with a regular appointment scheduled between 1 December 2020 and 29 April 2021 and who provided informed consent were included. Available medical records, vaccination certificates, and a questionnaire were analyzed. Results: we included 136 lung cancer patients (NSCLC n = 113, 83.1%, SCLC n = 23, 16.9%). A correct pneumococcal vaccination according to national recommendations was performed in 9.4% (12/127) of the patients. A correct vaccination was performed for tetanus in 50.4% (66/131), diphtheria in 34.4% (44/128), poliomyelitis in 25.8% (33/128), tick-borne encephalitis in 40.7% (24/59), hepatitis A in 45.5% (7/11), hepatitis B in 38.5% (5/13), shingles in 3.0% (3/101), measles in 50.0% (3/6), pertussis in 47.7% (62/130), influenza in 54.4% (74/136), and meningococcal meningitis in 0% (0/2) of the patients. Conclusion: adherence to pneumococcal vaccinations, as well as to other vaccinations, is low in lung cancer patients.

14 April 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SBStilla Bauernfeind
Stilla Bauernfeind
GHGunnar Huppertz
Gunnar Huppertz
KMKarolina Mueller
Karolina Mueller
FHFlorian Hitzenbichler
Florian Hitzenbichler
LHLoredana Hardmann
Loredana Hardmann
BSBernd Salzberger
Bernd Salzberger
Reactogenicity of coronavirus disease 2019 (COVID-19) vaccines can result in inability to work. The object of this study was to evaluate health care workers’ sick leave after COVID-19 vaccination and to compare it with sick leave due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and quarantine leave. A multi-center cross-sectional survey was conducted at Regensburg University Medical Center and ten teaching hospitals in South-East Germany from July 28th to October 15th 2021. Of 2662 participants, 2309 (91.8%) were fully vaccinated without a history of SARS-CoV-2 infection. Sick leave after first/second vaccination occurred in 239 (10.4%) and 539 (23.3%) participants. In multivariable logistic regression, the adjusted odds ratio for sick leave after first/second vaccination compared to BNT162b2 was 2.26/3.72 for mRNA-1237 (95% confidence interval (CI) 1.28-4.01/1.99-6.96) and 27.82/0.48 for ChAdOx1-S (95% CI 19.12-40.48/0.24-0.96). The actual median sick leave was one day (interquartile range (IQR) 0-2) after any vaccination. 251 participants (9.4%) reported a history of SARS-CoV-2 infection (median sick leave 14 days, IQR 10-21), 353 (13.3%) were quarantined at least once (median quarantine leave 14 days, IQR 10-14). Sick leave due to SARS-CoV-2 infection (4642 days) and quarantine leave (4710 days) accounted for 7.7 times more loss of workforce than actual sick leave after first and second vaccination (1216 days) in all fully vaccinated participants. Sick leave after COVID-19 vaccination is frequent and associated with the vaccine applied. COVID-19 vaccination should reduce the much higher proportion of loss of workforce due to SARS-CoV-2 infection and quarantine.

25 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
SBStilla Bauernfeind
Stilla Bauernfeind
SESebastian Einhauser
Sebastian Einhauser
LTLeonid Tydykov
Leonid Tydykov
AMAnna-Lena Mader
Anna-Lena Mader
BSBernd Salzberger
Bernd Salzberger
DPDavid Peterhoff
David Peterhoff
In a previous study, we described a highly significant association between reactogenicity and SARS-CoV-2 RBD IgG titers and wild-type neutralization capacity in males after basic vaccination with BNT162b2. The objective of this study was to assess whether this benefit was long lasting and also evident after BNT162b2 booster vaccination. Reactogenicity was classified into three groups: no or minor injection site symptoms, moderate (not further classified) and severe adverse reactions (defined as any symptom(s) resulting in sick leave). We initially compared 76 non-immunocompromised individuals who reported either no or minor injection site symptoms or severe adverse reactions after second vaccination. In total, 65 of them took part in another blood sampling and 47 were evaluated after booster vaccination. 26 weeks after second vaccination, men who reported severe adverse reactions after second vaccination had 1.7-fold higher SARS-CoV-2 RBD IgG titers (p = 0.025) and a 2.5-fold better neutralization capacity (p = 0.006) than men with no or only minor injection site symptoms. Again, no association was found in women. Reactogenicity of BNT162b2 booster vaccination was different from second vaccination according to our classification and was no longer associated with SARS-CoV-2 RBD IgG titers or wild-type neutralization capacity. To conclude, after BNT162b2 basic vaccination, the association between reactogenicity and humoral immune response in men persisted over time but was no longer detectable after BNT162b2 booster vaccination.